blockbuster potential value.

This deal was reveled yesterday for Genzyme to license the ISIS antisense technology.
http://www.reuters.com/article/marketsNews/idUKN0743219220080107?rpc=44
"Isis shares leap on Genzyme cholesterol deal
Mon Jan 7, 2008 6:24pm EST
NEW YORK (Reuters) - Genzyme Corp (GENZ.O: Quote, Profile, Research) said late on Monday it will license a promising new type of cholesterol drug from Isis Pharmaceuticals Inc (ISIS.O: Quote, Profile, Research) and could eventually pay Isis more than $1.5 billion in milestone payments and half the profit from its sales, lifting Isis shares 50 percent in after-hours trading.

The deal for mipomersen, now in late-stage trials, is a validation of Isis' long quest to perfect a technology called antisense and employ it in potential blockbuster medicines.

Genzyme, best known for its so-called orphan drugs to treat rare genetic diseases, said mipomersen would fit the company's specialty focus.

The deal for the product, which Genzyme first hopes to introduce for patients with a genetic tendency toward high cholesterol, would entitle Isis to an initial 30 percent share of profits. Its profit share would rise to 50 percent once global annual sales reach $2 billion or more.

"We believe it could prove to be the most effective lipid (blood fat) lowering agent for high risk patients for whom conventional therapies are not sufficient," said Henri Termeer, Genzyme's chief executive officer.

Isis Chief Executive Stanley Crooke said on November 14 at the Reuters Health Summit that the medicine was one of the most important drugs in biotechnology and its value could surpass Isis' market capitalization.

Under the deal announced on Monday, Genzyme said it will pay Isis $150 million, or $30 per share, to buy five million shares of its common stock. That is more than twice the $14.58 closing price of Isis shares on Monday. The stock rose after-hours to $21.90.

Genzyme said it will also pay Isis a $175 million upfront fee to license its drug."
The SP jumped 43% after close. Not bad off a market cap of $1.2Billion.
http://finance.yahoo.com/q?s=isis